CN114196593B - Lactobacillus plantarum P101 with high antioxidant activity and application thereof - Google Patents
Lactobacillus plantarum P101 with high antioxidant activity and application thereof Download PDFInfo
- Publication number
- CN114196593B CN114196593B CN202111652229.XA CN202111652229A CN114196593B CN 114196593 B CN114196593 B CN 114196593B CN 202111652229 A CN202111652229 A CN 202111652229A CN 114196593 B CN114196593 B CN 114196593B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- liver
- alcohol
- lactobacillus
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 66
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 66
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 66
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 30
- 230000000968 intestinal effect Effects 0.000 claims abstract description 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 8
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 8
- 108020004465 16S ribosomal RNA Proteins 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 4
- 210000004185 liver Anatomy 0.000 claims description 26
- 241000894006 Bacteria Species 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 13
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 108090001005 Interleukin-6 Proteins 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 102000003814 Interleukin-10 Human genes 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 239000006041 probiotic Substances 0.000 claims description 5
- 235000018291 probiotics Nutrition 0.000 claims description 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 206010019133 Hangover Diseases 0.000 claims description 2
- 230000000369 enteropathogenic effect Effects 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000770 proinflammatory effect Effects 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 13
- 230000036542 oxidative stress Effects 0.000 abstract description 12
- 239000003833 bile salt Substances 0.000 abstract description 8
- 230000004083 survival effect Effects 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 abstract description 6
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 3
- 208000004930 Fatty Liver Diseases 0.000 abstract description 2
- 230000002378 acidificating effect Effects 0.000 abstract description 2
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 abstract 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 abstract 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 28
- 239000007788 liquid Substances 0.000 description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- 230000001580 bacterial effect Effects 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 241000186660 Lactobacillus Species 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229940039696 lactobacillus Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 238000009630 liquid culture Methods 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 229940118019 malondialdehyde Drugs 0.000 description 7
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003254 radicals Chemical group 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 231100000753 hepatic injury Toxicity 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 230000004792 oxidative damage Effects 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 238000003794 Gram staining Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000007863 steatosis Effects 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 229940076144 interleukin-10 Drugs 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021121 fermented vegetables Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- -1 hydroxyl radicals Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012599 radical scavenging assay Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 231100000748 severe hepatic injury Toxicity 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a lactobacillus plantarum P101 with high antioxidant activity and application thereof, wherein the lactobacillus plantarum P101 is separated from farmhouse made pickled Chinese cabbage in Jian City of Jiangxi province, and the 16S rRNA sequence is shown as SEQ ID NO:1, the preservation number is CCTCC M2021108. The lactobacillus plantarum P101 has good antibacterial activity, and can remarkably inhibit the activity of intestinal pathogenic bacteria such as staphylococcus aureus, pseudomonas aeruginosa and the like; the lactobacillus plantarum P101 has stronger antioxidant activity, and in-vitro experimental results show that the clearance rate of the lactobacillus plantarum P101 to 1,1 diphenyl-2-trinitrophenylhydrazine (DPPH) and hydroxyl free radicals is obviously higher than that of lactobacillus rhamnosus GG (LGG), and in-vivo experimental results show that the lactobacillus plantarum P101 can effectively weaken oxidative stress injury induced by alcohol and inhibit body inflammatory reaction. The survival rate of the lactobacillus plantarum P101 in the acidic or high-bile salt environment is obviously higher than that of lactobacillus plantarum ZDY2013, and in addition, the lactobacillus plantarum P101 has outstanding benefits in relieving alcohol-induced steatohepatitis.
Description
Technical Field
The invention belongs to the fields of microbial technology and food fermentation, and particularly relates to lactobacillus plantarum P101 with high antioxidant activity and application thereof.
Background
Oxidative stress refers to a state in which oxidation and antioxidation in the body are unbalanced, and when the body is in the oxidative stress state, reactive Oxygen Species (ROS) accumulated in the body can cause free radical chain reaction by destroying biomolecules, and excessive free radicals can reduce body resistance, reduce cell turnover rate, induce oxidative damage, cause inflammation and aging, and the like. Oxidative stress is a major contributor to many diseases, such as: cardiovascular and cerebrovascular diseases, liver diseases and cancers. When the body is oxidized and the oxidation resistance is unbalanced, the contents of free radicals and Malondialdehyde (MDA) are increased, and the activity of antioxidant enzyme is reduced, so that oxidative damage is caused.
Long-term overdose often results in a range of chronic non-infectious liver diseases, mainly including the following stages: steatosis, steatohepatitis, alcoholic liver fibrosis and cirrhosis, which have a certain overlap between the pathological processes, are not independent of each other. In recent years, the mortality rate of alcoholic liver diseases is gradually increased, and the mortality rate has become one of the most serious health problems in most countries, and about 300 tens of thousands of people worldwide take excessive death (accounting for 5.3% of all deaths) in 2016 according to the global WHO alcohol and health status report in 2018, wherein 6.07 tens of thousands of people die from alcohol-induced cirrhosis. If a large amount of people drink wine for a long time, more than 90% of people can be subjected to steatosis, wherein 10% -35% of people can develop alcoholic hepatitis and liver fibrosis, and 8% -20% of people can develop liver cirrhosis. After alcohol enters a human body, on one hand, the proportion of gram-negative bacteria in the intestinal tract is increased by disturbing the intestinal flora; on the other hand, by disrupting the integrity of the intestinal barrier, intestinal permeability is increased, allowing more lipopolysaccharide to reach the liver via the portal circulation. Excess lipopolysaccharide can activate Kupffer cells in the liver, producing ROS and inflammatory cytokines, which are the onset of liver inflammation and fibrosis. Meanwhile, a large amount of acetaldehyde produced by alcohol metabolism in the liver has certain toxicity to liver cells, and can cause liver cell damage. Alcohol metabolism is also accompanied by the production of large amounts of ROS, which reduces the activity of antioxidant enzymes in the liver, causing oxidative stress, resulting in hepatocellular injury, peroxidation of liver lipids and steatosis.
Lactic acid bacteria are mainly present in nutrient rich environments, including dairy products, fermented meats and fish, sour dough, salted vegetables, etc. fermented foods. Lactic acid bacteria also survive in the healthy intestinal and genitourinary tracts of humans and animals and are an important component of the microflora. Lactic acid bacteria have strong probiotic functions, and are mainly expressed as being capable of being planted in intestinal tracts so as to play a role in regulating immunity; inhibiting bacterial overgrowth to maintain microecological balance of intestinal flora; inhibiting intestinal inflammation and improving intestinal barrier function; improving the antioxidant capacity of the organism, etc. The remarkable antioxidant activity of the lactobacillus is mainly realized by scavenging free radicals, chelating oxidation-promoting metal ions, generating antioxidant substances, regulating the activity of related enzymes and regulating intestinal microflora, so that the oxidative damage is relieved. A plurality of researches show that probiotics such as lactobacillus, bifidobacterium and the like have excellent antioxidation capability, can reduce the risk of ROS accumulation in a organism, and can play a role in alleviating oxidative damage to a certain extent. Therefore, it is important to screen lactic acid bacteria with high antioxidant activity.
At present, a plurality of lactobacillus plantarum with antioxidant activity are reported, but the defects of poor antibacterial effect or intolerance to the extreme environment of the gastrointestinal tract and the like are common in research. Wherein, chinese patent CN109182162A provides a plateau lactobacillus plantarum which has a certain antioxidant activity and can effectively remove free radicals in the organism, but has lower survival rate in intestinal juice and weaker gastrointestinal tolerance; chinese patent CN109182162A provides an antioxidant active lactobacillus plantarum with a preservation number of CGMCC15780, and the scavenging rate of hydroxyl radicals of the lactobacillus plantarum is low. Chinese patent CN111304117a provides a strain of lactobacillus plantarum GL-5, which is limited to tolerance studies on hydrogen peroxide. Therefore, the lactobacillus plantarum which has strong tolerance to organisms and high antioxidant activity is developed and researched, and has great significance and application value. In addition, chinese patent CN111437294a provides lactobacillus plantarum KLDS1.0344 and lactobacillus acidophilus KLDS1.0901 for the combined treatment of acute and chronic alcoholic liver injury, mainly by improving intestinal barrier, improving liver function, reducing inflammation level in the liver and increasing short chain fatty acid content in the intestinal tract. The invention aims to find a lactobacillus plantarum strain with high antioxidant activity and good probiotics, and can relieve alcohol-induced liver oxidative damage. In summary, the present invention has substantial differences from other patent publications.
Disclosure of Invention
The invention provides lactobacillus plantarum P101 (Lactobacillus plantarum P) 101 with high antioxidant activity and application thereof, and the lactobacillus plantarum P101 has good antibacterial activity, acid tolerance, bile salt tolerance and stronger antioxidant activity, and animal experiment results show that the lactobacillus plantarum P101 can effectively relieve alcoholic liver injury. Can be used for preparing medicines, health products and microecological preparations with intestinal flora regulating and antioxidant effects, and fruit and vegetable fermented beverage with effects of relieving alcoholic intoxication and protecting liver.
The invention is realized by the following technical scheme:
the high antioxidant activity lactobacillus plantarum P101 has a preservation number of CCTCC M2021108, the preservation place is China center for type culture collection of Wuhan, and the 16S rRNA sequence of the lactobacillus plantarum P101 is shown as SEQ ID NO: 1.
Another object of the invention is to provide lactobacillus plantarum P101, and its application in preparing medicines for inhibiting enteropathogenic bacteria.
Further, the pathogenic bacteria are staphylococcus aureus (Staphylococcus aureus) and pseudomonas aeruginosa (Pseudomonas aeruginosa).
Another object of the invention is to provide a lactobacillus plantarum P101, and its application in preparing health care products for regulating intestinal flora.
Another object of the invention is to provide a lactobacillus plantarum P101, its use for the preparation of immunomodulators.
Another object of the invention is to provide lactobacillus plantarum P101, which is applied to the preparation of antioxidants, antioxidative drugs or antioxidative health care products.
Another object of the invention is to provide a lactobacillus plantarum P101, its use in the preparation of fermented foods and probiotic preparations for alleviating hangover and protecting liver.
Compared with the prior art, the invention has the beneficial effects that:
1. the lactobacillus plantarum P101 provided by the invention has good antibacterial activity, and can obviously inhibit the activities of common pathogenic bacteria staphylococcus aureus and pseudomonas aeruginosa;
2. the lactobacillus plantarum P101 provided by the invention has good acid tolerance and bile salt tolerance, and the survival rate in an acid culture medium with pH=3 and a culture medium containing 0.3% of bovine bile salt is obviously higher than that of Gao Naisuan lactobacillus plantarum ZDY2013 (Chinese patent CN 105255752A);
3. the antioxidant activity of the lactobacillus plantarum P101 provided by the invention is obviously higher than that of lactobacillus rhamnosus GG (LGG);
4. the lactobacillus plantarum P101 provided by the invention has a remarkable effect in relieving alcoholic liver injury, and the benefit is remarkably stronger than that of the reported lactobacillus plantarum C88.
Drawings
FIG. 1 shows colony morphology and gram staining results of Lactobacillus plantarum P101.
Fig. 2 shows the bacteriostatic effect of different strains on staphylococcus aureus and pseudomonas aeruginosa, with significance among different letters.
Fig. 3 shows the survival rate of lactobacillus plantarum P101 in MRS liquid medium at ph=3 and 0.3% bovine bile salt, where a is the survival rate of lactobacillus plantarum P101 in MRS liquid medium at ph=3 and B is the survival rate of lactobacillus plantarum P101 in 0.3% bovine bile salt MRS liquid medium, with significance between different letters.
FIG. 4 is an evaluation of in vitro antioxidant activity of Lactobacillus plantarum P101: a is the clearance rate of 1,1 diphenyl-2-trinitrophenylhydrazine (DPPH), B is the clearance rate of hydroxyl free radicals, and the significance among different letters is achieved.
Fig. 5 is a graph showing the results of alleviating alcohol-induced hepatotoxicity in mice by lactobacillus plantarum P101: a is glutamic pyruvic transaminase (ALT) activity, B is glutamic oxaloacetic transaminase (AST) activity, C is alkaline phosphatase (AKP) activity, D is total Triglyceride (TG) content, E is Total Cholesterol (TC) content, and different letters have significance.
Fig. 6 is a graph showing the results of alleviating alcohol-induced oxidative stress in the liver of mice by lactobacillus plantarum P101: a is the level of Malondialdehyde (MDA) in the liver, B is the level of superoxide dismutase (SOD) in the liver, and different letters have significance.
Fig. 7 shows the results of the lactobacillus plantarum P101 alleviating alcohol-induced inflammatory responses in mice: a is the level of tumor necrosis factor-alpha (TNF-alpha) in serum, B is the level of interleukin-1 beta (IL-1 beta) in serum, C is the level of interleukin-6 (IL-6) in serum, D is the level of interleukin-10 (IL-10) in serum, and different letters have significance.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be clearly and completely described in the following examples. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are commercially available and conventional products, and manufacturers are not identified.
Examples
1 isolation and purification of lactic acid bacteria
1.1 isolation of lactic acid bacteria
After taking 200 mu L of fermentation liquor from a fermented vegetable sample made by peasant household in Jian area of Jiangxi, enriching and culturing for 24 hours in an MRS liquid culture medium, diluting the culture liquor by a concentration gradient through sterile PBS, sucking 100 mu L of the culture liquor, uniformly coating the culture liquor onto an improved MRS solid culture medium containing 1% calcium carbonate, and repeating each concentration twice. Placing the strain in a constant temperature incubator at 37 ℃ for culturing for 48 hours, and observing the conditions of colony and transparent ring generation, thereby being convenient for further separation and purification.
1.2 purification culture
Single colonies with clear boundaries and transparent circles were selected using an inoculating loop, streaked on MRS solid medium, and the plates were placed in an anaerobic incubator at 37℃for 24-48h. And continuously scribing for 3-5 times, taking a drop of 3% hydrogen peroxide which is prepared at present, dripping the drop on a glass slide, picking a single colony on a solid culture medium, inoculating the single colony into the 3% hydrogen peroxide drop, uniformly mixing, and taking the generated bubble as positive by a catalase test, and taking the non-generated bubble as negative by the catalase test, wherein the negative bacterial strain by the catalase test is a suspected lactic acid bacterial strain. The selected colonies were subcultured on MRS solid medium by streaking for 24-48 hours to obtain monoclonal colonies. The single colony is picked for liquid culture for 20 hours, and the equivalent bacterial liquid and 50 percent of glycerol are fully and evenly mixed and stored at the temperature of minus 80 ℃.
1.3 Strain Activity screening
The bacterial liquid stored in 25% glycerol was inoculated into fresh MRS liquid medium according to an inoculum size of 2% and cultured in a constant temperature incubator at 37℃for 10 hours as seed bacterial liquid for the next experiment. Inoculating the seed bacterial liquid into a centrifuge tube filled with MRS liquid culture medium according to the inoculation amount of 2%, culturing for 16h in a constant temperature incubator at 37 ℃ for secondary culture, selecting a strain P101 with better growth, and preserving at 4 ℃ for later use.
2 identification of lactic acid bacteria
2.1 gram staining
The monoclonal strain is selected for gram staining, specific steps are referred to a gram staining kit instruction, and then an ordinary optical microscope is used for oil-microscopic observation and photographing.
2.2 sequence analysis of 16S rRNA of Strain P101
Fresh strain P101 broth was obtained and PCR amplification was performed using bacterial 16S rRNA universal primers:
the upstream primer is as follows: 27F AGAGTTTGATCTGGCTCAG
The downstream primer is: 1492 and 1492R GGTTACCTTGTTACGACTT
PCR amplification system:
20. Mu.L of the reaction system comprises: mix,10 μl; primers (10. Mu.M): an upstream primer (Forward), 0.5. Mu.L, a downstream primer (Reverse), 0.5. Mu.L; 2. Mu.L of DNA template (strain P101 broth); ddH 2 O，10μL。
PCR reaction conditions: (1) 95 ℃ for 5min; (2) 95 ℃ for 30s; (3) 56 ℃ for 30s; (4) 72 ℃ for 1min; (2) - (4) cycling 35 times; (5) 72℃for 10min.
1.5% agarose gel electrophoresis confirmed product bands: the 1500bp band is provided with a target band, and the product is sent to Shanghai worker for sequence analysis.
Sequencing results show that the strain P101 is lactobacillus plantarum, and the 16S rRNA sequence of the strain P101 is shown as SEQ ID NO: 1.
3 determination of antibacterial Property
Centrifuging 8000r/min lactobacillus culture solution for 16 hr for 10min, and collecting supernatant. Taking 100 μl of activated indicator bacteria, and adjusting the concentration of indicator bacteria to 1×10 8 CFU/mL, staphylococcus aureus and Pseudomonas aeruginosa were cultured overnight at 1% inoculum size for 12h at night, and the bacterial concentration was adjusted to 10 6 Coating plates on corresponding culture mediums after CFU/mL, placing a culture dish on an ultra-clean workbench for half opening for 10min after coating, placing oxford cups on a solid culture medium, adding 200 mu L of seed bacterial liquid supernatant preserved in 1.3, culturing at 37 ℃ steadily for 18h, observing and measuring the diameter of a bacteriostasis ring of each bacterial liquid, and performing three groups of experiments in parallel.
The antibacterial experiment result shows that the antibacterial effect of the strain on staphylococcus aureus and pseudomonas aeruginosa is obviously higher than that of LGG.
4 evaluation of acid resistance
Inoculating lactobacillus strain at 2% inoculum size into centrifuge tube containing fresh MRS liquid culture medium, culturing in 37 deg.C constant temperature incubator for 16 hr, centrifuging 8000r/min of cultured lactobacillus culture solution for 10min, discarding supernatant, adding acidic MRS liquid culture medium (pH=3) prepared in advance with equal volume, mixing, recording as 0 hr, culturing in 37 deg.C constant temperature incubator for 2 hr, recording as 2 hr, respectively taking 100 μL of 0 hr and 2 hr bacterial solutions, and gradient diluting (10 times -1 ，10 -2 ，10 -3 ，10 -4 ，10 -5 ，10 -6 ，10 -7 ) Take 10 -5 ，10 -6 ，10 -7 The diluted bacterial liquid of (2) is plated, and is counted after being cultured for 24-48 hours in a constant temperature incubator at 37 ℃, and three experiments are performed in parallel.
Survival = 2h (CFU/mL)/0 h (CFU/mL) ×100%
5 evaluation of bile salt resistance
Inoculating lactobacillus strain into centrifuge tube containing fresh MRS liquid culture medium at 2% inoculation amount, culturing in constant temperature incubator at 37deg.C for 16 hr, centrifuging for 10min at 8000r/min, removing supernatant, adding equal volume of MRS liquid culture medium containing 0.3% bovine bile salt, mixing, and recordingCulturing for 0 hr in a constant temperature incubator at 37deg.C for 3 hr, taking 100 μl of bacterial liquid for 0 hr and 3 hr, respectively, and performing gradient dilution (10) -1 ，10 -2 ，10 -3 ，10 -4 ，10 -5 ，10 -6 ，10 -7 ) Take 10 -5 ，10 -6 ，10 -7 The diluted bacterial liquid of (2) is plated, cultured in a constant temperature incubator at 37 ℃ for 24-48 hours, counted and subjected to 3 groups of experiments in parallel.
Survival = 3h (CFU/mL)/0 h (CFU/mL) ×100%
The evaluation results of acid resistance and cholate resistance show that the acid resistance and cholate resistance of the strain are obviously higher than that of lactobacillus plantarum ZDY2013.
6. Evaluation of in vitro Oxidation resistance
6.1 Sample preparation
Inoculating lactobacillus inoculation liquid into 2mL of MRS liquid culture medium according to the inoculation amount of 4%, and standing and culturing for 16h to obtain the culture liquid of the strain. Centrifuging at 8000r/min for 10min to collect thallus, washing twice with sterile physiological saline, re-suspending thallus, and adjusting thallus density OD 600 nm 0.6842 +/-0.0642 for standby.
6.2 DPPH radical scavenging assay
Taking 2mL of physiological saline suspension of lactobacillus to be detected in a 10mL centrifuge tube, adding 2mL of DPPH solution (DPPH is prepared by dissolving with absolute ethyl alcohol, and the final concentration is 0.4 mmol/L), uniformly mixing, placing the mixture at room temperature for shading reaction for 30min, centrifuging the mixture at the rotating speed of 8000r/min for 10min, taking 200 mu L of supernatant, measuring the absorbance of the sample at the wavelength of 517nm, and repeating the experiment for 3 times.
Note that: the blank group sample uses equal volume absolute ethyl alcohol sample to replace DPPH-absolute ethyl alcohol solution, the control group sample uses equal volume distilled water to replace sample solution, and the equal volume distilled water and absolute ethyl alcohol mixed solution is used for blank zeroing. The clearance rate is calculated according to the following formula: wherein A is Control For the absorbance of the control group, A Sample of For the absorbance of the sample group, A Blank space Is a blank control.
DPPH radical scavenging rate = 1- (a) Sample of －A Blank space )/A Control ×100％
6.2 determination of the free radical scavenging Rate of hydroxyl groups
Taking 1mL of phenanthroline (2.6 mmol/L), sequentially adding 1mL of Phosphate Buffer Solution (PBS) (pH=7.4) and 1mL of distilled water, fully mixing, and adding 1mL of FeSO 4 Uniformly mixing the solution (2.5 mmol/L); 1mL of H is added 2 O 2 0.5mL of sample to be detected is added into the solution (20 mmol/L) respectively; the absorbance was measured at 536nm after 1.5h in a 37℃water bath, and 3 experiments were repeated using PBS as a control.
Hydroxyl radical clearance = (As-Ap)/(Ab-Ap) ×100%
Wherein: as is the absorbance of the sample; ap is the absorbance of the sample after the water bath and Ab is the absorbance of PBS.
The in vitro antioxidant results of lactobacillus plantarum P101 showed that DPPH clearance and hydroxyl radical clearance were significantly higher than LGG (see figure 4).
7 study on alleviating effect of lactobacillus plantarum P101 on alcoholic liver injury of mice
7.1 animal experiments
24C 57BL/6 male adult mice (8-10 weeks) were purchased from Hunan Stokes Lekkera laboratory animals Co. One week after the adaptive feeding, the animals were randomly divided into 3 groups (n=8), normal control group (PBS): control liquid feed+pbs (200 μl); alcohol model group (EtOH): alcohol liquid feed + PBS (200 μl); lactic acid bacteria treatment group (EtOH)&P101): alcohol liquid feed + lactic acid bacteria (10) 8-9 CFU/mL,200 μl); the alcohol liver model is established by using NIAAA method, the specific implementation method is that the control liquid feed is used for 5 days of adaptive feeding, from the 6 th day, the normal control group is continuously fed with the control liquid feed, the alcohol model group and the lactobacillus treatment group are fed with the alcohol liquid feed containing 5 percent, the alcohol liquid feed group is fed in the morning of 16 th day for one time of alcohol gastric lavage (5 g/kg), the control group is replaced by the same amount of dextrin, the mice are euthanized after 9 hours of gastric lavage, eyeballs are taken out, and liver samples are stored at-80 ℃.
7.2 analysis of hepatotoxicity index in serum
Storing the blood obtained by animal collection in a common sterilization centrifuge tube, standing at 4deg.C overnight, centrifuging at 4,000r/min for 10min, collecting supernatant, packaging, storing in a clean common sterilization centrifuge tube, freezing at-80deg.C, purchasing a liver function index determination kit such as ALT, AST, AKP, TG, TC from Nanjing built biological Co., ltd., and analyzing according to manufacturer specification.
ALT, AST and AKP levels in serum are commonly used to evaluate indicators of liver function. As shown in fig. 5 a-C, alcohol exposure significantly increased ALT, AST and AKP activity in mouse serum compared to control, indicating impaired liver function. The interference group of the lactobacillus plantarum P101 is obviously reduced compared with the alcohol model group, which shows that the lactobacillus plantarum P101 can effectively improve the liver function damage. In addition, the TC and TG content of the alcohol model group was significantly increased, indicating that steatosis occurred in the liver, whereas the TC and TG content was significantly decreased after the dry process of lactobacillus plantarum P101, indicating that lactobacillus plantarum P101 was able to improve liver lipid metabolism and reduce lipid accumulation in the liver.
7.3 determination of oxidative stress level in liver tissue
Taking part of liver tissue to prepare 10% liver tissue homogenate, quantifying protein, freezing at-80 ℃, adopting SOD and MDA oxidative stress index determination kit (built by Nanjing) and operating according to the specification of the manufacturer.
Alcohol is metabolized mainly in the liver, which is prone to cause oxidative stress in the liver, while the levels of SOD and MDA in the liver can fully reflect the antioxidant level of the liver. As shown in the results of fig. 6, MDA levels in the liver of mice were significantly increased and SOD levels were significantly decreased after alcohol exposure, indicating that alcohol was able to induce oxidative stress in the liver of mice, causing the liver to suffer damage. The oxidative stress in the liver is slowed down after the intervention of the lactobacillus plantarum P101, and the liver damage degree is also relieved, which indicates that the lactobacillus plantarum P101 can relieve the alcohol-induced liver damage by playing an antioxidant role.
7.4 determination of inflammatory cytokine content in serum
Oxidative stress can further trigger inflammatory responses, which in turn lead to more severe liver injury, and the pro-inflammatory cytokines TNF- α, IL-1β, IL-6 and anti-inflammatory cytokine IL-10 in serum were measured using an enzyme-linked immunosorbent assay kit (Shanghai marine organism) according to the manufacturer's instructions.
Excessive TNF- α, IL-1β and IL-6 cytokine secretion resulted in inflammatory responses, which showed significant increases in TNF- α, IL-1β and IL-6 in mouse serum after alcohol intake compared to control group. Compared with the alcohol model group, the human serum TNF-alpha, IL-1 beta and IL-6 in the serum are obviously reduced after the intervention of the lactobacillus plantarum P101, which indicates that the lactobacillus plantarum P101 can relieve the alcohol-induced liver injury by playing an anti-inflammatory role. In addition, the expression level of the anti-inflammatory factor IL-10 is obviously increased compared with that of an alcohol model group, and the lactobacillus plantarum P101 also has better anti-inflammatory effect.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present application and not for limiting the same; although the present application has been described in detail with reference to preferred embodiments, those of ordinary skill in the art will appreciate that: modifications may be made to the specific embodiments of the present application or equivalents may be substituted for part of the technical features, which are all included in the scope of the technical solutions claimed herein.
SEQUENCE LISTING
<110> university of Nanchang
<120> Lactobacillus plantarum P101 with high antioxidant activity and application thereof
<130> 2021.11.27
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1462
<212> DNA
<213> Lactobacillus plantarum
<400> 1
cagggggcgg tcttataatg cagtcgaacg actctggtat tgattggtgc ttgcatcatg 60
atttacattt gagtgagtgg cgaactggtg agtaacacgt gggaaacctg cccagaagcg 120
ggggataaca cctggaaaca gatgctaata ccgcataaca acttggaccg catggtccga 180
gtttgaaaga tggcttcggc tatcactttt ggatggtccc gcggcgtatt agctagatgg 240
tggggtaacg gctcaccatg gcaatgatac gtagccgacc tgagagggta atcggccaca 300
ttgggactga gacacggccc aaactcctac gggaggcagc agtagggaat cttccacaat 360
ggacgaaagt ctgatggagc aacgccgcgt gagtgaagaa gggtttcggc tcgtaaaact 420
ctgttgttaa agaagaacat atctgagagt aactgttcag gtattgacgg tatttaacca 480
gaaagccacg gctaactacg tgccagcagc cgcggtaata cgtaggtggc aagcgttgtc 540
cggatttatt gggcgtaaag cgagcgcagg cggtttttta agtctgatgt gaaagccttc 600
ggctcaaccg aagaagtgca tcggaaactg ggaaacttga gtgcagaaga ggacagtgga 660
actccatgtg tagcggtgaa atgcgtagat atatggaaga acaccagtgg cgaaggcggc 720
tgtctggtct gtaactgacg ctgaggctcg aaagtatggg tagcaaacag gattagatac 780
cctggtagtc cataccgtaa acgatgaatg ctaagtgttg gagggtttcc gcccttcagt 840
gctgcagcta acgcattaag cattccgcct ggggagtacg gccgcaaggc tgaaactcaa 900
aggaattgac gggggcccgc acaagcggtg gagcatgtgg tttaattcga agctacgcga 960
agaaccttac caggtcttga catactatgc aaatctaaga gattagacgt tcccttcggg 1020
gacatggata caggtggtgc atggttgtcg tcagctcgtg tcgtgagatg ttgggttaag 1080
tcccgcaacg agcgcaaccc ttattatcag ttgccagcat taagttgggc actctggtga 1140
gactgccggt gacaaaccgg aggaaggtgg ggatgacgtc aaatcatcat gccccttatg 1200
acctgggcta cacacgtgct acaatggatg gtacaacgag ttgcgaactc gcgagagtaa 1260
gctaatctct taaagccatt ctcagttcgg attgtaggct gcaactcgcc tacatgaagt 1320
cggaatcgct agtaatcgcg gatcagcatg ccgcggtgaa tacgttcccg ggccttgtac 1380
acaccgcccg tcacaccatg agagtttgta acacccaaag tcggtggggt aacctttaga 1440
accagcgcta aacgggacaa gg 1462
Claims (5)
1. Application of lactobacillus plantarum P101 with high antioxidant activity in preparation of medicines for inhibiting enteropathogenic bacteria;
the pathogenic bacteria are staphylococcus aureus and pseudomonas aeruginosa;
the lactobacillus plantarum P101 has a preservation number of CCTCC M2021108, the preservation place is the China center for type culture Collection of Wuhan, and the 16S rRNA sequence is shown as SEQ ID NO: 1.
2. Use of lactobacillus plantarum P101 according to claim 1 for the manufacture of a health care product for regulating intestinal flora.
3. Use of lactobacillus plantarum P101 according to claim 1 for the preparation of an immunomodulator for decreasing the expression level of the pro-inflammatory cytokines TNF- α, IL-1 β, IL-6 in serum and increasing the expression level of the anti-inflammatory cytokine IL-10.
4. Use of lactobacillus plantarum P101 according to claim 1 for the preparation of antioxidants or antioxidant health products.
5. Use of lactobacillus plantarum P101 according to claim 1 for the preparation of a probiotic preparation related to anti-hangover and liver protection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111652229.XA CN114196593B (en) | 2021-12-30 | 2021-12-30 | Lactobacillus plantarum P101 with high antioxidant activity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111652229.XA CN114196593B (en) | 2021-12-30 | 2021-12-30 | Lactobacillus plantarum P101 with high antioxidant activity and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114196593A CN114196593A (en) | 2022-03-18 |
| CN114196593B true CN114196593B (en) | 2023-07-28 |
Family
ID=80657444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111652229.XA Active CN114196593B (en) | 2021-12-30 | 2021-12-30 | Lactobacillus plantarum P101 with high antioxidant activity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114196593B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114921361B (en) * | 2022-04-19 | 2023-07-18 | 浙江大学 | Lactobacillus plantarum ZY08 with effect of improving alcoholic liver injury and application thereof |
| CN116716203B (en) * | 2022-11-28 | 2024-02-02 | 朗恒科技集团有限公司 | Lactobacillus plantarum SC75-2-2 with high oxidation resistance and application thereof |
| CN117070426B (en) * | 2023-10-12 | 2023-12-19 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for improving alcoholic fatty liver disease and application thereof |
| CN117778269B (en) * | 2024-01-08 | 2024-10-22 | 宁夏大学 | Lactobacillus plantarum NXU0014 and application thereof |
| CN118272274B (en) * | 2024-05-20 | 2024-08-09 | 齐齐哈尔大学 | Lactic acid bacteria starter and application thereof in preparation of blueberry corn peptide fermentation liquor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105255752B (en) * | 2015-04-27 | 2018-08-17 | 南昌大学 | High acid plant lactobacillus ZDY2013 |
| CN109234189A (en) * | 2018-08-17 | 2019-01-18 | 甘肃普诺贝康生物科技有限责任公司 | One plant of lactobacillus plantarum strain BX62 and its application with oxidation resistance |
| CN111100810B (en) * | 2019-12-20 | 2022-04-05 | 华南农业大学 | Lactobacillus plantarum DNB1, and extracellular polysaccharide and application thereof |
| CN111235070B (en) * | 2020-03-18 | 2022-03-08 | 河北农业大学 | Breast milk infant source lactobacillus plantarum BF _15 and application thereof |
| CN114164149B (en) * | 2021-11-29 | 2023-10-03 | 南昌大学 | Lactobacillus plantarum P101 for relieving obesity and lead toxicity and application thereof |
-
2021
- 2021-12-30 CN CN202111652229.XA patent/CN114196593B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114196593A (en) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114196593B (en) | Lactobacillus plantarum P101 with high antioxidant activity and application thereof | |
| US8034606B2 (en) | Acid tolerant Lactobacillus sakei probio-65 with the ability of growth suppression of pathogenic microorganisms and the anti-allergic effect | |
| CN111925961B (en) | Lactobacillus plantarum Lp2 and application thereof | |
| CN110373367B (en) | Lactobacillus plantarum with pesticide degradation activity, preparation method and application thereof | |
| CN110157645B (en) | Lactobacillus salivarius Y4 and application thereof | |
| CN111534447A (en) | Lactobacillus johnsonii and application thereof | |
| KR20230154400A (en) | Lactobacillus plantarum hom3201 strain and its live bacterial preparation, preparation method and application | |
| CN116396894A (en) | Lactobacillus plantarum with function of inhibiting growth of various common pathogenic bacteria | |
| CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
| CN110257302B (en) | Screening method and application of lactobacillus strain with antioxidant capacity | |
| KR102675187B1 (en) | Lactobacillus plantarum KCC-24 and composition comprising the same | |
| KR20160063024A (en) | Lactobacillus plantarum KCC-24 and composition comprising the same | |
| CN117683670A (en) | Lactobacillus plantarum FMBL L23036CNN, yoghurt starter, yoghurt and application thereof | |
| CN117327616A (en) | Lactiplantibacillus plantarum ZN1 and application thereof | |
| CN113717887B (en) | Goose-source lactobacillus plantarum and application thereof | |
| CN113881592B (en) | Lactobacillus reuteri and application thereof | |
| CN116478859A (en) | Lactic acid bacteria and microorganism preparation capable of tolerating hypochlorous acid water and application thereof | |
| KR20170045190A (en) | Lactobacillus plantarum KCC-24 and composition comprising the same | |
| CN110241052B (en) | Lactobacillus plantarum GSLP-7 capable of highly producing folic acid and application thereof | |
| CN113930367A (en) | Lactic acid bacteria with cholesterol-reducing performance and application thereof | |
| CN111154694A (en) | Microbial fermentation inoculant and preparation method and application thereof | |
| CN114395514B (en) | Lactobacillus acidophilus, microbial inoculum and application thereof | |
| Aritonang et al. | Characterization of lactic acid bacteria from buffalo dairy product (dadiah) as potential probiotics | |
| Sonwane et al. | Isolation And Identification Of Bacterial Culture From Curd And Pickle | |
| CN116179419A (en) | Lactobacillus plantarum with lipid-lowering function and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |